[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-lymphoblastic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-lymphoblastic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100582301","a-swiss-assessment-of-hypothalamic-pituitary-adrenal-axis-suppression-after-glucocorticoid-therapy-for-leukemia-and-lymphoblastic-lymphoma-in-children-100582301",false,"NCT06861530","A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children","A Swiss Prospective Multicenter Longitudinal Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children: An Explorative Study","LeukemiaCort","Inclusion Criteria:\n\n* diagnosed with ALL or LBL\n* treated for at least 21 sequential days with glucocorticoids between the 01.07.2024 and the 30.06.2027 at the Childrens University Hospital of Basel or at the Childrens Hospital of Aarau\n* lnformed consent can be obtained from the patient\\'s legal representatives (and the patient if at least 14 years of age) within week 2 of treatment with glucocorticoids\n\nExclusion Criteria:\n\n\\- Contraindication to the administration of intravenous synthetical ACTH (Synacthen®): extremely rare cases of known or suspected hypersensitivity to Synacthen®.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","OBSERVATIONAL","Plain Language Summary:\n\nBackground Glucocorticoids are stress hormones produced by the human body to control inflammation and regulate the immune system. Cortisol is the most well-known example of a glucocorticoid. These stress hormones are essential for the bodys healthy functioning.\n\nTo treat certain types of cancer, such as leukemia (blood cancer) in children, glucocorticoids are administered as medications in large quantities. This helps rapidly reduce the number of cancer cells in the body but also leads to the suppression of the body's natural glucocorticoid production, causing a deficiency.\n\nThis deficiency can be particularly dangerous for children with leukemia, as their immune defenses are already weakened by chemotherapy, leading to an increased risk of infections. Moreover, the signs of glucocorticoid deficiency in children with leukemia are often indistinguishable from the side effects of chemotherapy, making the deficiency harder to detect.\n\nObjectives The aim of the study is to understand how frequently and for how long the body's natural glucocorticoid production is impaired in children treated for lymphoblastic leukemia and lymphoblastic lymphoma. Additionally, the goal is to identify which children are at particularly high risk.\n\nBy gaining a better understanding, this study may help to improve the detection and treatment of glucocorticoid deficiency in children with blood cancer.\n\nMethods Regular low-dose ACTH tests will be conducted to assess the bodys natural glucocorticoid production during and after treatment. To avoid placing additional burden on children who are already heavily affected by the disease, these tests will only be performed when there is already a venous access established and the children are in the hospital for treatment reasons.",[25,26,27],"Adrenal Insufficiency","Leukemia, Lymphoblastic, Acute, Pediatric","Lymphoma, Lymphoblastic",[29,30,31,32,33,34,35],"Adrenal insufficiency","leukemia","leukaemia","childhood","pediatric","paediatric","glucocorticoid","RECRUITING","2026-05-04",{"date":39,"type":40},"2026-05-08","ACTUAL",{"date":42,"type":40},"2024-08-13",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"University Children's Hospital Basel","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100598340","phase-1-a-study-of-ctd402-in-t-alllbl-patients-100598340","NCT07070219","A Study of CTD402 in T-ALL\u002FLBL Patients","A Single-Arm, Open-Label, Multi-Center, Phase 1b\u002F 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)","TENACITY-01","Key Inclusion Criteria:\n\n1. Male or female, ≥ 12 years of age.\n2. Participants with body weight ≥ 40 kilogram.\n3. Relapsed or refractory T-ALL\u002FLBL is defined as one of the following:\n\n   1. Relapsed or refractory disease after two or more lines of systemic therapy;\n   2. The first relapse occurs within 12 months after first remission;\n   3. Relapse after allogeneic HSCT and must be ≥100 days from HSCT prior to screening period.\n4. The presence of bone marrow lymphoblasts is ≥ 5% as determined by morphologic evaluation or evidence of extramedullary disease at screening.\n5. Have eligible HLA-matched related donor (MRD) or unrelated donor (URD), eligible haploidentical donor (HID) or syngeneic donors.\n6. Adequate organ function\n7. Karnofsky PS ≥ 60 (for participants age ≥ 16) or Lansky PS ≥ 60 (for participants \\\u003C 16) at screening.\n\nKey Exclusion Criteria:\n\n1. Participants with concomitant genetic syndromes associated with bone marrow failure states or any other known bone marrow failure syndrome.\n2. Active central nervous system (CNS) involvement\n3. Participants with following cardiac conditions will be excluded:\n\n   1. History of heart failure New York Heart Association (NYHA) class III or IV;\n   2. History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.\n4. Primary immune deficiency.\n5. Presence of uncontrolled infections.\n6. Known history of infection with the human immunodeficiency virus (HIV); hepatitis C virus and syphilis.\n7. Active or latent hepatitis B virus infection\n8. Epstein-Barr virus (EBV), Cytomegalovirus (CMV) DNA or IgM positive at screening.","12 Years",{"count":58,"type":21},54,"INTERVENTIONAL",[61,62],"PHASE1","PHASE2","The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed\u002Frefractory T-ALL\u002FLBL patients.\n\nParticipants with relapsed\u002Frefractory T-ALL\u002FLBL over the age of 12 will be eligible to participate.\n\nParticipants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL.\n\nPatients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.",[65,27],"Acute Lymphocytic Leukemia Refractory",[67,68],"CAR-T Therapy","relapsed\u002Frefractory","2026-02-04",{"date":71,"type":40},"2026-02-05",{"date":73,"type":40},"2025-10-07",{"date":75,"type":21},"2028-12-30",{"name":77,"class":78},"BIOHENG THERAPEUTICS US LLC","INDUSTRY",8]